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ABSTRACT 
 
Background 
COPD exacerbation incidence rates are often ascertained retrospectively, through 
patient recall and self-reports. We compared exacerbation ascertainment through patient self-
reports and single physician chart review to central adjudication by a committee and explored 
determinants and consequences of misclassification.  
Methods 
Self-reported exacerbations (event-based definition) in 409 primary care COPD 
patients participating in the ICE COLD ERIC cohort were ascertained 6-monthly over 3 
years. Exacerbations were adjudicated by single experienced physicians and an adjudication 
committee who had information from patient charts. We assessed the accuracy (sensitivities 
and specificities) of self-reports and single physician chart review against a central 
adjudication committee (reference standard). We used multinomial logistic regression and 
bootstrap stability analyses to explore determinants of misclassifications. 
Results 
The adjudication committee identified 648 exacerbations, corresponding with an 
incidence rate of 0.60±0.83 exacerbations/patient-year and a cumulative incidence proportion 
of 58.9%. Patients self-reported 841 exacerbations (incidence rate 0.75±1·01, incidence 
proportion 59.7%). Sensitivity/specificity of self-reports were 84%/76%, those of single 
physician chart review between 89-96% and 87-99%. The multinomial regression model and 
bootstrap selection showed that having experienced more exacerbations was the only factor 
consistently associated with under- and over-reporting of exacerbations (under-reporters: 
relative risk ratio 2.16, 95% CI 1.76-2.65; over-reporters: relative risk ratio 1.67, 95% CI 
1.39-2.00). 
Conclusions 
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Patient 6-month recall of exacerbation events are inaccurate. This may lead to 
inaccurate estimates of incidence measures and underestimation of treatment effects. The use 
of multiple data sources combined with event adjudication could substantially reduce sample 
size requirements and possibly cost of studies. 
  
Clinical Trial Registration: www.ClinicalTrials.gov, NCT00706602 
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INTRODUCTION 
Good measurement is central to good science. Similarly, accurate ascertainment of 
endpoints in observational studies and randomised controlled trials (RCTs) is crucial to 
minimise endpoint misclassification. Concerns about misclassification of outcomes prompted 
the use of endpoint adjudication committees (ACs), particularly in large cardiovascular 
RCTs.1,2 The value of endpoint ACs has been debated recently because they require 
considerable investments and some studies found no discrepancy between effect estimates 
based on centrally adjudicated endpoints or adjudications made by single local investigators.3–
5 However, in studies assessing misclassification of different types of outcomes, the degree of 
misclassification increased with increasing ambiguity (subjectiveness) of the outcome at 
issue.6  
There is little evidence on when to use outcome ACs in studies with chronic 
obstructive pulmonary disease (COPD) patients. Candidate outcomes likely to benefit from 
adjudication by a central committee in COPD studies include cause-specific mortality and 
exacerbations. The Towards a Revolution in COPD Health (TORCH)7 and Understanding 
Potential Long-term Impacts on Function with Tiotropium (UPLIFT)8 trials had ACs for 
cause-specific mortality and found substantial disagreement between local investigators and 
ACs.9,10 COPD exacerbations have rarely been adjudicated centrally by experts blinded to 
treatment or exposures,11,12 despite their importance as an outcome measure.13–16 
Ascertainment of exacerbations is challenging because of mimicking differential diagnoses 
(e.g. worsening of heart failure, pulmonary embolism), since the cause of exacerbations often 
cannot be determined and because several sources of information (patient self-reports, patient 
charts, emergency healthcare visits) are needed to avoid missing or misclassifying 
exacerbations.  
Exacerbation rates for enrolment or evaluation in clinical trials are usually ascertained 
through patient recall or single physicians who review the available information about a 
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patient and make judgments on the occurrence of exacerbations (expert adjudication). 
However, little is known about the accuracy of these reports. Misclassification of 
exacerbations may lead to biased effect estimates. The exact nature of the bias may be 
different for (risk) ratio measures and difference measures and can also depend on whether 
exposure is misclassified (noncompliance in trials).17,18 Our aim was to evaluate the accuracy 
of the ascertainment of COPD exacerbations through patient recall and self-reports and single 
physician chart reviews against a reference standard of a central AC. In addition, we explored 
predictors of inaccurate ascertainment of COPD exacerbations. Finally, we explored potential 
consequences of misclassification for treatment effects in trials and sample size requirements.  
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MATERIAL AND METHODS 
The unabridged version of the Material and Methods section is presented in e-Appendix 1. 
 
Study design and study subjects  
This study was nested within the prospective International collaborative effort on 
chronic obstructive lung disease: exacerbation risk index cohorts (ICE COLD ERIC) and 
comprised 3 years. 409 primary care patients (≥40 years of age) from the Netherlands (n=258) 
and Switzerland (n=151) with COPD (post-bronchodilator forced expiratory volume in 1 
second [FEV1]/forced vital capacity [FVC]<0.7, FEV1<80% predicted) were included. All 
patients provided written informed consent. The study has been approved by the ethics 
committees in Zurich (EK-1519) and Amsterdam (MEC-08-073). Detailed information on the 
study design19 and results20–22 were published elsewhere. 
 
Definition and ascertainment of exacerbations  
We used an event-based definition of exacerbations that required 1) an unscheduled 
physician contact in a hospital, private practice or by telephone for worsening of dyspnoea, 
cough, increased sputum production and/or a change in sputum colour AND 2) an electronic 
or hand-written documentation in the patient record of a new prescription or dosage increase 
of systemic steroids and/or new prescription of an antibiotic.19,23  
We used three different methods to ascertain exacerbations. First, through patient 
recall and self-reports, with data gathered every six months through personal interview by 
experienced study nurses. Second, through independent review of patient charts and study 
case report forms by seven single experienced physicians. These experts individually and 
independently decided about occurrence of exacerbations, onset date (prescription/dosage 
increase or first pill taken) and treatment setting. To distinguish between new exacerbations 
and slow-to resolve ones or relapses, an interval of at least one month was required. Third, 
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through central AC meetings where a group of experts (formed by the independent reviewers) 
reached final consensus on exacerbations for each patient (reference standard). The AC 
meetings were organised by study staff that neither participated in the discussions nor had 
influence on decisions made. The expert committee discussed instances where decisions on 
exacerbations were discrepant, based on their individual decisions, re-review of patient charts 
and case report forms.  
 
Analyses  
We tabulated total number of recalled and self-reported exacerbations against total 
number of centrally adjudicated exacerbations at the level of patients. We calculated 
exacerbation incidence rates and cumulative incidence proportions as self-reported by 
patients, as decided by individual experts (for incidence proportions) and as adjudicated in the 
AC. We calculated sensitivity and specificity of patient self-reports and independent review of 
patient charts and study case report forms by single physicians compared to the reference 
standard of centrally adjudicated exacerbations (categorised: no exacerbation/≥1 
exacerbations). To explore predictors of misclassification, we generated a patient-specific rate 
difference reflecting the difference between self-reported and adjudicated exacerbation rate 
and categorised the variable into correct self-reports, over- and under-reports (predictors: sex, 
age, education, living situation, working status, COPD severity, health status (feeling 
thermometer)24,25, quality of life (Chronic Respiratory Questionnaire),26 depression/anxiety 
(Hospital Anxiety And Depression Scale),27 number of comorbidities, previous 
exacerbations). We used multinomial logistic regression and bootstrap stability analyses. We 
conducted all analyses using Stata Statistical Software version 13.1, StataCorp LP, College 
Station, TX. 
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RESULTS 
Patient characteristics and adjudicated exacerbations 
57.5% (233/409) of the patients were male. Overall mean age was 67.3±10.0 years, 
FEV1 in % predicted 55.4±16.6 and MRC score 1.9±1.5. 261 (63.8%) patients were classified 
in Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II, 89 (21.8%) in 
GOLD stage III and 59 (14.4%) in GOLD stage IV.  
In total, across all 409 patients, the AC identified 648 exacerbations during the three 
study years. 94% (n=606) of the exacerbations were outpatient-treated, 6% (n=38) were 
treated in a hospital setting and for four exacerbations the treatment setting was unknown. 168 
(41.1%) patients did not have an exacerbation during the study time, 101 patients (24.7%) had 
one, 41 patients (10.0%) had two, 34 (8.3%) patients had three and 65 patients (15.9%) had 
four or more exacerbations. The incidence rate was 0.60±0.83 exacerbations/patient-year and 
the incidence proportion (having experienced at least one exacerbation) 58.9% (n=241). The 
total person-time at risk was 1153.4 years and the mean length of follow-up was 2.82±0.49 
years. 
 
Accuracy of exacerbations  
The patients recalled and self-reported 841 exacerbations over three years. Incidence 
rate of self-reported exacerbations was 0.75±1.01 exacerbations/patient-year and incidence 
proportion 59.7% (n=244). The total number of exacerbations during the three study years 
was correctly reported by 48% (196/409) of the patients; 65% of the patients who correctly 
reported the number of exacerbations had no exacerbations (127/196). The proportion of over-
reports on exacerbations was higher than the proportion of under-reports (139/409, 34% vs. 
74/409, 18%). Thus there was more false positive than false negative misclassification (Table 
1).  
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Using the centrally adjudicated exacerbations as a reference standard, patient recall 
and self-reports of exacerbations achieved a sensitivity of 84% and a specificity of 76%. 
Independent review of patient charts and study case report forms by the 7 single physicians 
achieved sensitivities ranging from 89-96% and specificities ranging from 87-99% (Table 2).  
 
Determinants of misclassification 
Table 3 shows the results of the multinomial regression model. “Number of previous 
exacerbations” (adjudicated) and “feeling thermometer” were the only predictors for which 
the inclusion fraction exceeded our 67% threshold; for number of previous exacerbations in 
100%, for feeling thermometer in 67.7%. Compared to patients who correctly reported the 
total number of exacerbations, patients who under- or over-reported experienced a higher 
number of exacerbations (under-reporters: relative risk ratio [RRR] 2.16, 95% confidence 
interval [CI] 1.76-2.65; over-reporters: RRR 1.67, 95% CI 1.39-2.00) (RRR describes the 
multiplicative effect of a unit increase in each predictor on the odds of over- or under-
reporting instead of correctly self-reporting exacerbations [base category]). The feeling 
thermometer was not associated with over- or underreporting (under-reporters: RRR 0.99, 
95% CI 0.97-1.02; over-reporters: RRR 0.99, 95% CI 0.97-1.01). The reduced multinomial 
regression model that includes only these two selected variables is presented in e-Table 1.  
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DISCUSSION 
Our study showed that patient 6-month recall of COPD exacerbations, the most 
commonly used method to assess exacerbation rates in COPD research, was fairly inaccurate 
when compared against an AC as the reference standard. Having experienced a higher number 
of exacerbations in the past was the only predictor associated with misclassification. The 
independent assessments of comprehensive patient information on exacerbations from patient 
charts and study case report forms by single experienced physicians were more accurate than 
patient self-reports only and, for some physicians, approximated the accuracy of adjudication 
by an AC.  
In general, patients tended to over-report more than to under-report exacerbations. The 
AC’s feedback showed that a major reason for over-reporting was that patients correctly 
remembered physician encounters or hospitals visits, but that many of these events were 
unrelated to COPD exacerbations. For example, patients received antibiotics for urinary tract 
infection or were admitted to hospitals because of an injury. These events were clearly 
documented in the patient charts of the general practitioners. This highlights the advantage of 
going beyond patient self-reports for outcomes that are difficult to ascertain, such as COPD 
exacerbations. Some misclassifications concerned differential diagnoses such as pulmonary 
embolism, and some over-reporting occurred because patients referred to new exacerbations 
whereas the AC did not classify them as new but as slow recoveries from previous 
exacerbations.  
Little is known so far about the accuracy of patient recall of exacerbation events and 
single physician judgements based on patient chart reviews, the two most commonly used 
methods to ascertain COPD exacerbation rates. A recently published study used medical 
records and two blinded investigators to verify patient reports on exacerbations but did not 
report on agreement of expert adjudication with patient self-reports.12 Investigators of the 
Women’s Health Initiative trial found that sensitivity of patient recall and self-reports on 
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cardiovascular events, compared to single expert assessment, was highly dependent on the 
type of outcome. Self-reported events like angina, peripheral vascular disease and congestive 
heart failure attained substantially lower sensitivities (38-49%) when compared against 
central adjudication than “hard” endpoints such as coronary bypass surgery or angioplasty 
(84-90%). The accuracy of single expert judgements compared to central adjudication was 
higher, with sensitivities/specificities similar to those observed in our study.6 These findings 
support the assumption that the value of ACs increases for outcomes that are experienced by 
patients as less determinate compared to more distinct events such as surgeries. Patients 
probably experience outpatient-treated exacerbations as changes of their underlying disease 
symptomatology and pharmacologic therapy. Therefore, exacerbation events offer less 
anchors in time and patients will presumably have more difficulties recalling them in 6-
months interviews. Assessed retrospectively through patient recall and self-reports, they are 
more prone to misclassification, particularly in patients with frequent exacerbations, multiple 
co-morbidities and older age.  
One crucial consequence of endpoint misclassifications is their impact on treatment 
effect estimates and, consequently, sample size requirements. Although non-differential 
misclassification (of a binary outcome) often leads to underestimation of true treatment 
effects, this is not always the case.18,28 While these phenomena are often well appreciated in 
observational research, there is still sparse awareness in RCTs that inaccurate measurement 
may have a serious impact on validity and precision of effect estimates.17  
To illustrate the potential impact of treatment effect estimates misclassification and 
sample size requirements for RCTs using the outcome exacerbation incidence proportion, we 
repeated a meta-analysis of RCTs on long-acting beta-agonists (LABAs) as first-line 
maintenance therapy vs. placebo.29 Like in our study, exacerbations were assessed using 
patient self-reports and event-based definition. We assumed several exemplary scenarios for 
misclassifications, using sensitivities/specificities of a) 80%/70%, b) 84%/76% (as our study 
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detected), c) 80%/85%, d) 95%/85%. We recalculated the meta-analysis adjusting for the 
assumed examples using logitem command (Stata Statistical Software version 13.1). The 
pooled odds ratio of LABA versus placebo decreased (i.e. resulted in larger treatment effects) 
from 0.81 (95% CI 0.75-0.88) as reported in the original study to a) 0.59 (95% CI 0.43-0.81), 
b) 0.65 (95% CI 0.52-0.81), c) 0.69 (95% CI 0.58-0.81), d) 0.73 (95% CI 0.63-0.84). To 
delineate the consequences of AC deployment for sample size requirements in future trials, 
we calculated sample sizes using the original published and corrected ORs. Depending on 
baseline risk for exacerbations and degree of expected misclassifications, elimination of 
exacerbation misclassification led up to 2- to 6- fold reductions in required sample (Figure 1; 
e-Appendix 2).  
The impact of misclassification on sample size requirements may be the same when 
using exacerbation incidence rates. In a simulation model derived from the misclassification 
based on ICECOLDERIC’s ACs, we found that the incidence rate ratio was unbiased but the 
standard error of the incidence rate ratio was substantially inflated (i.e. less precision, e-
Appendix 3). 
In light of the available evidence and results of our study, we recommend the use of 
expert ACs in clinical trials and observational studies in which COPD patients are at high risk 
for exacerbations and in which COPD exacerbations are a key outcome. If it is deemed 
infeasible to centrally adjudicate exacerbations or in low-risk populations, we recommend 
single expert adjudication of information on exacerbations from case report forms, patient 
charts and other sources if available. If only patient self-reports on exacerbations are available 
and no additional patient charts assessment can be conducted, we recommend frequent (at 
least monthly) collection of patient recall and self-reports on exacerbations. Finally, the use of 
an AC, through its reduction of misclassification, leads to substantially larger or more precise 
effect estimates, thus greatly reducing sample size requirements for RCTs. This may lead to 
substantial pay-offs in terms of feasibility and cost of RCTs and observational studies. 
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Strengths of the study include that our population represents a large and diverse group 
of COPD patients from primary care. We used a clearly specified definition of exacerbations. 
Exacerbations were very carefully assessed by experienced and well-trained study nurses in 
patient friendly language. Also the ACs were carefully conducted in a standardised way by 
experienced physicians.  
A limitation of our study is that even though we put great effort in accurate assessment 
and adjudication of exacerbations, we still may have missed or misclassified some. No 
standardised definition and measurement methods exist and different definitions may lead to 
different results.30,31 We used an event-based definition, the most commonly used definition 
in drug development and clinical trials which is used by FDA and EMA to approve new 
therapies. This definition required documented worsening of symptoms and dosage 
increase/new prescription of systemic corticosteroids and/or antibiotics. We therefore 
accepted to miss mild exacerbations (ATS/ERS Task Force23) which involve an increase in 
respiratory symptoms that can be controlled by increase of usual medication. Our time 
criterion of ≥1 month between events is arbitrary to some extent. We used this interval 
because recent EXACT-PRO instrument data showed that it often takes patients weeks to 
recover from an exacerbation.32 Finally, the sensitivities/specificities we provide for single 
physicians may be somewhat inflated because these experts were members of the AC, thereby 
violating the strict criterion that index test and reference standard have to be independent. 
In conclusion, 6-month recall of exacerbation events are inaccurate when compared 
against an AC, leading to imprecise estimates of incidence rates and incidence proportions 
and underestimation of treatment effects. The use of several data sources combined with event 
adjudication could substantially reduce sample size requirements and possibly cost of studies. 
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Tables 
 
Table 1: Total number of exacerbations per patient: patient 6-months recall and self-
reports compared to adjudicated exacerbations by an adjudication committee (reference 
standard) 
 Total number of centrally adjudicated exacerbations per patient 
0 1 2 3 4 5 6 7 8 9 10 11 12 Total 
T
o
ta
l 
n
u
m
b
er
 o
f 
se
lf
-r
e
p
o
rt
ed
 e
x
a
ce
rb
a
ti
o
n
s 
p
er
 p
a
ti
en
t 
0 127* 24 5 4 2 2 1 0 0 0 0 0 0 165 
1 26 40 5 2 1 3 0 0 0 0 0 0 0 77 
2 9 17 10 4 2 1 0 0 0 0 0 0 0 43 
3 3 6 7 10 2 3 2 1 0 0 0 0 0 34 
4 1 7 3 6 2 3 2 1 0 0 0 1 0 26 
5 0 3 5 4 0 4 1 1 0 0 0 0 0 18 
6 0 2 4 1 6 1 2 0 0 0 0 0 0 16 
7 0 2 2 0 2 0 0 0 0 0 0 0 0 6 
8 0 0 0 2 2 0 1 2 1 0 0 0 1 9 
9 2 0 0 1 0 0 0 1 1 0 0 0 0 5 
10 0 0 0 0 0 1 0 0 0 0 0 0 0 1 
11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
12 0 0 0 0 0 2 0 0 2 0 0 0 0 4 
13 0 0 0 0 0 1 1 0 0 0 0 0 0 2 
14 0 0 0 0 1 0 0 0 0 0 1 0 0 2 
15 0 0 0 0 0 0 0 0 0 0 0 1 0 1 
Total 168 101 41 34 20 21 10 6 4 0 1 2 1 409 
 
*Bold cells: number of correct self-reported exacerbations. E.g. see “Total number of exacerbations per patient, 
adjudicated in AC”, column “1 exacerbation”: 40 patients reported correctly that they had 1 exacerbation, 24 
patients under-reported their exacerbations (they reported no exacerbation while they had had 1 according to the 
adjudication committee), 37 (77 minus 40) patients over-reported their exacerbations (reported they had had >1 
exacerbations while they had had 1 according to the adjudication committee)  
 
  
22 
 
Table 2: Sensitivities and specificities of patient recall and self-reports and single 
experienced physician chart review compared to centrally adjudicated exacerbations by 
an adjudication committee (reference standard) (n=409) 
Source*) Numbe
r of 
patients 
Sensitivity 
(%)† 
Specificity 
(%)† 
Patient recall and self-reports 409 84.2 75.6 
Physician 1 CH 151 88.8 94.4 
Physician 2 CH 151 93.8 97.2 
Physician 3 CH 151 91.3 98.6 
Physician 1 NL 258 94.4 96.9 
Physician 2 NL 257 95.0 86.6 
Physician 3 NL 258 96.3 94.8 
Physician 4 NL 258 90.7 96.9 
*CH = Switzerland; NL = The Netherlands 
†Exacerbations categorised: no exacerbation vs. ≥1 exacerbation  
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Table 3: Multinomial regression model showing the relative risk ratios of the predictors 
for under- or over-reporting exacerbations compared to the base category correctly self-
reporting exacerbations (n=403) 
Variable RRR* Standard 
error 
p-value     95% CI 
Patients who under-reported exacerbations (n=74) 
Sex† 
  Female 
 
0.53 
 
0.21 
 
0.105 
 
0.24 – 1.14 
Age (years) 1.05 0.23 0.024 1.01 – 1.09 
Education† 
  Secondary school 
  Intermediate vocational  
  High vocational / university 
 
0.98 
0.91 
1.25 
 
0.45 
0.51 
0.83 
 
0.973 
0.865 
0.737 
 
0.40 – 2.43 
0.30 – 2.76 
0.34 – 4.62 
Living situation† 
  Living with partner 
  Living with children and/or partner 
 
0.79 
3.49 
 
0.30 
1.94 
 
0.543 
0.024 
 
0.38 – 1.67 
1.17 – 10.38 
Working situation† 
  Not working 
 
1.00 
 
0.47 
 
0.998 
 
0.40 – 2.53 
Feeling thermometer‡ 0.99 0.01 0.590 0.97 – 1.02 
CRQ dyspnoea domain  1.01 0.14 0.934 0.77 – 1.33 
CRQ fatigue domain 0.79 0.14 0.934 0.80 – 1.33 
CRQ mastery domain 1.01 0.18 0.960 0.71 – 1.45 
FEV1 (litres) 1.00 0.38 1.000 0.48 – 2.10 
HADS anxiety score 1.11 0.06 0.061 1.00 – 1.23 
HADS depression score 0.89 0.06 0.103 0.78 – 1.02 
Number of comorbidities 0.93 0.070 0.378 0.79 – 1.09 
Number of exacerbations‡ 2.16 0.23 <0.001 1.76 – 2.65 
Patients who correctly reported exacerbations (base category, n=193) 
Patients who over-reported exacerbations (n=136) 
Sex† 
  Female 
 
0.74 
 
0.22 
 
0.317 
 
0.42 – 1.33 
Age (years) 1.01 0.02 0.617 0.98 – 1.04 
Education† 
  Secondary school 
  Intermediate vocational  
  High vocational / university 
 
0.54 
0.61 
0.64 
 
0.18 
0.26 
0.32 
 
0.068 
0.244 
0.364 
 
0.28 – 1.05 
0.27 – 1.40 
0.24 – 1.69 
Living situation† 
  Living with partner 
  Living with children and/or partner 
 
0.78 
1.50 
 
0.22 
1.68 
 
0.379 
0.364 
 
0.45 – 1.36 
0.62 – 3.63 
Working situation† 
  Not working 
 
1.21 
 
0.44 
 
0.592 
 
0.60 – 2.47 
Feeling thermometer‡ 0.99 0.01 0.290 0.97 – 1.01 
CRQ dyspnoea domain  0.88 0.10 0.240 0.71 – 1.09 
CRQ fatigue domain 0.97 0.13 0.807 0.74 – 1.27 
CRQ mastery domain 1.12 0.16 0.429 0.85 – 1.47 
FEV1 (litres) 1.19 0.35 0.549 0.68 – 2.07 
HADS anxiety score 1.07 0.04 0.083 0.99 – 1.17 
HADS depression score 0.94 0.05 0.221 0.85 – 1.04 
Number of comorbidities 1.07 0.06 0.271 0.95 – 1.20 
Number of exacerbations‡ 1.67 0.15 <0.001 1.39 – 2.00 
Abbreviations and scores: FEV1: Forced expiratory volume in 1 second; CRQ=Chronic Respiratory 
Questionnaire (scores: 0-7/maximal to no impairment); HADS: Hospital Anxiety and Depression Scale (scores: 
0-21/no to most severe anxiety/depression); feeling thermometer (score: 0-100/worst to best health status). 
*RRR = Relative risk ratio. RRR describes the multiplicative effect of a unit increase in each predictor on the 
odds of over- or under-reporting instead of correctly self-reporting exacerbations (base category). †Comparison 
against following categories: Sex: male / Education: lowest level / Living situation: living alone / Working 
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situation: still working. ‡In the bootstrap stability analysis (500 replicates, selection p<0.1, threshold of bootstrap 
inclusion fraction (BIF) 67%) the inclusion fractions for the variables number of adjudicated exacerbations 
during study (BIF=100%) and feeling thermometer (BIF=67.7%) exceeded the 67% threshold.    
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Figure legends: 
 
Figure 1: Recalculation of meta-analysis of long-acting bronchodilators vs. placebo trials 
with exacerbations as the outcome, based on four scenarios of misclassification and 
derivation of sample size requirements with and without use of adjudication committee 
 
 
Legend: The figure shows four examples of sample size calculations that compare 
calculations using the originally published pooled OR (0.81) of the meta-analysis of LABA 
vs. placebo trials (where self-reports of exacerbations were used) against ORs attained from 
recalculated meta-analyses that were adjusted for four assumed scenarios of misclassifications 
(detected when adjudication committees were used), for a low risk (10% risk over 1 year) and 
a high risk (50% risk over 1 year) population situations: Example a) sensitivity and specificity 
of 80% and 70%, respectively, results in OR 0.59; b) 84%/76% in OR 0.65 (such as detected 
in our study), c) 80%/85% in OR 0.69, d) 95%/85% in OR 0.73. 
